|
1
|
Maute L, Grünwald V, Weikert S, Kube U,
Gauler T, Kahl C, Burkholder I and Bergmann L: Therapy of mRCC
beyond mTOR-inhibition in clinical practice: results of a
retrospective analysis. J Cancer Res Clin Oncol. 140:823–827. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Najjar YG and Rini BI: Novel agents in
renal carcinoma: a reality check. Ther Adv Med Oncol. 4:183–194.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun M, Thuret R, Abdollah F, Lughezzani G,
Schmitges J, Tian Z, Shariat SF, Montorsi F, Patard JJ, Perrotte P
and Karakiewicz PI: Age-adjusted incidence, mortality, and survival
rates of stage-specific renal cell carcinoma in North America: a
trend analysis. Eur Urol. 59:135–141. 2011. View Article : Google Scholar
|
|
4
|
Huebner J, Micke O, Muecke R, Buentzel J,
Prott FJ, Kleeberg U and Senf B: User rate of complementary and
alternative medicine (CAM) of patients visiting a counseling
facility for CAM of a German comprehensive cancer center.
Anticancer Res. 34:943–948. 2014.PubMed/NCBI
|
|
5
|
Saghatchian M, Bihan C, Chenailler C,
Mazouni C, Dauchy S and Delaloge S: Exploring frontiers: use of
complementary and alternative medicine among patients with
early-stage breast cancer. Breast. 23:279–285. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bolarinwa IF, Orfila C and Morgan MR:
Determination of amygdalin in apple seeds, fresh apples and
processed apple juices. Food Chem. 170:437–442. 2015. View Article : Google Scholar
|
|
7
|
Tanaka R, Nitta A and Nagatsu A:
Application of a quantitative 1H-NMR method for the determination
of amygdalin in Persicae semen, Armeniacae semen, and Mume fructus.
J Nat Med. 68:225–230. 2014. View Article : Google Scholar
|
|
8
|
Lee J, Zhang G, Wood E, Rogel Castillo C
and Mitchell AE: Quantification of amygdalin in nonbitter,
semibitter, and bitter almonds (Prunus dulcis) by UHPLC-(ESI)QqQ
MS/MS. J Agric Food Chem. 61:7754–7759. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moss RW: The laetrile controversy. The
Cancer Industry. The Classic Expose on the Cancer Establishment.
First Equinox Press; Brooklyn, NY: pp. 131–152. 1996
|
|
10
|
Curt GA: Unsound methods of cancer
treatment. Princ Pract Oncol Updates. 4:1–10. 1990.
|
|
11
|
PDQ Cancer Complementary and Alternative
Medicine Editorial Board Laetrile/Amygdalin (PDQ®): Health
Professional Version PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002–2015
|
|
12
|
Moss RW: Patient perspectives: Tijuana
cancer clinics in the post-NAFTA era. Integr Cancer Ther. 4:65–86.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moertel CG, Fleming TR, Rubin J, Kvols LK,
Sarna G, Koch R, Currie VE, Young CW, Jones SE and Davignon JP: A
clinical trial of amygdalin (Laetrile) in the treatment of human
cancer. N Engl J Med. 306:201–206. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moertel CG, Ames MM, Kovach JS, Moyer TP,
Rubin JR and Tinker JH: A pharmacologic and toxicological study of
amygdalin. JAMA. 245:591–594. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ames MM, Moyer TP, Kovach JS, Moertel CG
and Rubin J: Pharmacology of amygdalin (laetrile) in cancer
patients. Cancer Chemother Pharmacol. 6:51–57. 1981.PubMed/NCBI
|
|
16
|
Newell GR and Ellison NM: Ethics and
designs: laetrile trials as an example. Cancer Treat Rep.
64:363–365. 1980.PubMed/NCBI
|
|
17
|
Wahab MF, Breitbach ZS, Armstrong DW,
Strattan R and Berthod A: Problems and pitfalls in the analysis of
amygdalin and its epimer. J Agric Food Chem. 63:8966–8973. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Makarević J, Rutz J, Juengel E, Kaulfuss
S, Reiter M, Tsaur I, Bartsch G, Haferkamp A and Blaheta RA:
Amygdalin blocks bladder cancer cell growth in vitro by diminishing
cyclin A and cdk2. PLoS One. 9:e1055902014. View Article : Google Scholar
|
|
19
|
Qian L, Xie B, Wang Y and Qian J:
Amygdalin-mediated inhibition of non-small cell lung cancer cell
invasion in vitro. Int J Clin Exp Pathol. 8:5363–5370.
2015.PubMed/NCBI
|
|
20
|
Chen Y, Ma J, Wang F, Hu J, Cui A, Wei C,
Yang Q and Li F: Amygdalin induces apoptosis in human cervical
cancer cell line HeLa cells. Immunopharmacol Immunotoxicol.
35:43–51. 2013. View Article : Google Scholar
|
|
21
|
Chang HK, Shin MS, Yang HY, Lee JW, Kim
YS, Lee MH, Kim J, Kim KH and Kim CJ: Amygdalin induces apoptosis
through regulation of Bax and Bcl-2 expressions in human DU145 and
LNCaP prostate cancer cells. Biol Pharm Bull. 29:1597–1602. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang WL, Yu CC, Chen CS and Guh JH:
Tubulin-binding agents down-regulate matrix metalloproteinase-2 and
-9 in human hormone-refractory prostate cancer cells - a critical
role of Cdk1 in mitotic entry. Biochem Pharmacol. 94:12–21. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Visconti R, Della Monica R, Palazzo L,
D'Alessio F, Raia M, Improta S, Villa MR, Del Vecchio L and Grieco
D: The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint
robustness and sensitivity to antimicrotubule cancer drugs. Cell
Death Differ. 22:1551–1560. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang WT, Catto JW and Meuth M:
Differential response of normal and malignant urothelial cells to
CHK1 and ATM inhibitors. Oncogene. 34:2887–2896. 2015. View Article : Google Scholar
|
|
25
|
Carcagno AL, Marazita MC, Ogara MF, Ceruti
JM, Sonzogni SV, Scassa ME, Giono LE and Cánepa ET: E2F1-mediated
upregulation of p19INK4d determines its periodic expression during
cell cycle and regulates cellular proliferation. PLoS One.
6:e219382011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuan H, Meng X, Guo W, Cai P, Li W, Li Q,
Wang W, Sun Y, Xu Q and Gu Y: Transmembrane-bound IL-15-promoted
epithelial-mesenchymal transition in renal cancer cells requires
the Src-dependent Akt/GSK-3β/β-catenin pathway. Neoplasia.
17:410–420. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He H and Magi-Galluzzi C:
Epithelial-to-mesenchymal transition in renal neoplasms. Adv Anat
Pathol. 21:174–180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang X, Ren J, Yan L, Tang Y, Zhang W, Li
D, Zang Y, Kong F and Xu Z: Cytoplasmic expression of pontin in
renal cell carcinoma correlates with tumor invasion, metastasis and
patients' survival. PLoS One. 10:e01186592015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shimazui T, Kojima T, Onozawa M, Suzuki M,
Asano T and Akaza H: Expression profile of N-cadherin differs from
other classical cadherins as a prognostic marker in renal cell
carcinoma. Oncol Rep. 15:1181–1184. 2006.PubMed/NCBI
|
|
30
|
Cheng C, Wan F, Liu L, Zeng F, Xing S, Wu
X, Chen X and Zhu Z: Overexpression of SATB1 is associated with
biologic behavior in human renal cell carcinoma. PLoS One.
9:e974062014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang J, Yao X, Zhang J, Dong B, Chen Q,
Xue W, Liu D and Huang Y: Hypoxia-induced downregulation of miR-30c
promotes epithelial-mesenchymal transition in human renal cell
carcinoma. Cancer Sci. 104:1609–1617. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gervais ML, Henry PC, Saravanan A, Burry
TN, Gallie BL, Jewett MA, Hill RP, Evans AJ and Ohh M: Nuclear
E-cadherin and VHL immunoreactivity are prognostic indicators of
clear-cell renal cell carcinoma. Lab Invest. 87:1252–1264. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ho MY, Tang SJ, Chuang MJ, Cha TL, Li JY,
Sun GH and Sun KH: TNF-α induces epithelial-mesenchymal transition
of renal cell carcinoma cells via a GSK3β-dependent mechanism. Mol
Cancer Res. 10:1109–1119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Harada K, Miyake H, Kusuda Y and Fujisawa
M: Expression of epithelial-mesenchymal transition markers in renal
cell carcinoma: impact on prognostic outcomes in patients
undergoing radical nephrectomy. BJU Int. 110:E1131–E1137. 2012.
View Article : Google Scholar : PubMed/NCBI
|
